Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

An anticancer pharmaceutical composition

An anti-cancer drug and composition technology, which can be used in drug combinations, anti-tumor drugs, pharmaceutical formulations, etc., and can solve problems such as difficulty in forming effective drug concentrations.

Inactive Publication Date: 2006-12-13
山东同科供应链股份有限公司
View PDF9 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the excessive expansion and hyperplasia of solid tumors, the interstitial pressure, tissue elastic pressure, fluid pressure and interstitial viscosity are all higher than those of the surrounding normal tissues. Therefore, it is difficult for conventional chemotherapy to form an effective drug concentration in the tumor (see Kong Qingzhong "Intratumoral placement of cisplatin plus systemic carmustine in the treatment of rat brain tumors" "Journal of Surgical Oncology" 69 pages 76-82 (1998) (Kong Qet al., J Surg Oncol.1998 Oct; 69 (2 ):76-82), simply increasing the dosage is limited by systemic reactions

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0105] Put 90 mg of PLGA (a copolymer of lactic acid and glycolic acid) with a molecular weight of 10,000 into a container, add 100 ml of dichloromethane, dissolve and mix well, add 10 mg of wortmannin (WM), re-shake, and vacuum dry to remove organic matter. solvent. The dried solid composition is shaped immediately, subpackaged and sterilized by radiation to obtain an anticancer drug composition containing 10% wortmannin by weight. The drug release time of the anticancer drug composition in the physiological saline in vitro is 15-20 days, and the drug release time in the mouse subcutaneous is about 30-40 days.

Embodiment 2

[0107] The method step of being processed into anticancer drug composition is identical with embodiment 1, but contained active ingredient is:

[0108] a) 1-40% by weight of benzopyran, 6-aryl-2-morphol-4-yl-pyran-4-yl, 6-aryl-2-morphol-4-yl-4H -thiopyran-4-yl, 2-(4-morpholinyl)-8-phenylchromone, 1-(2-hydroxy-4-morpholin-4-yl-phenyl)-ethylidene), Kinase inhibitors, vanillin, 2-aminopurine, 7-ethyl-10-hydroxycamptothecin, 3-cyano-6-hydrazonomethyl-5-(4-pyridyl)pyridine-[1H] -2-1. Phenylbutyrate; or

[0109] b) 1-40% by weight of 3-aminobenzamide, benzamide, 3,4-dihydromethoxyisoquinoline-1(2H)-benzamide, polymerase inhibitor, polymerase Inhibitors, amino-substituted 2-arylbenzimidazole-4-carboxamides, benzimidazole-4-carboxamides, tricyclic lactam hydrogen sulfide, tricyclic benzimidazole carboxamides; or

[0110] c) 1-40% by weight of benzimidazole, 1H-tricyclic benzimidazole carboxamide, 2-aryl-1H-benzimidazole-4-carboxamide, 2-phenyl-1H-benzimidazole- 4-carboxamide, 2-(4...

Embodiment 3

[0112] Put 80mg of pharmaceutical excipients (EVAc) into a container, add 100ml of dichloromethane to dissolve and mix well, then add 20mg of 2-(4-morpholinyl)-8-phenylchromone, shake well and then vacuum dry to remove the organic solvent . The dried solid composition is shaped immediately, subpackaged and then sterilized by radiation to obtain an anticancer drug composition containing 20% ​​by weight of 2-(4-morpholinyl)-8-phenylchromone. The drug release time of the anticancer drug composition in the physiological saline in vitro is 14-24 days, and the drug release time in the mouse subcutaneous is about 20-35 days.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates the anti-cancer drugs. The drugs comprise medicinal findings and DNA duplicate inhibiting agent. The DNA duplicate inhibiting agent, from polymeric (ADP- ribose) polymerization inhibitor and DNA-dependence protease inhibitor, destructs the DNA refinishing function in tumor cell, and reduces the survivability. The medicinal findings comprises degradable absorbing high molecular polymer, and at the course of degrading and absorbing, the findings can release the DNA duplicate inhibiting agent into the tumor parts, reducing the toxicity reaction and keeping effective drug concentration. The anti-cancer drugs also comprise nitrosourea drugs, which can reduce toxicity reaction and improve therapeutic efficacy.

Description

[0001] This application is a divisional application of 200410035923.7. (1) Technical field [0002] The invention relates to an anticancer drug composition, which belongs to the technical field of drugs. (2) Background technology [0003] The treatment of solid tumors mainly includes surgery, radiotherapy and chemotherapy. Among the various chemotherapeutic drugs used, nitrosourea anticancer drugs have obvious effects and have been widely used in various malignant tumors. However, further research found that the DNA repair function in many tumor cells increased significantly after the treatment. The latter often leads to enhanced resistance of tumor cells to nitrosourea anticancer drugs, resulting in treatment failure. [0004] It has recently been found that inactivation or inhibition of intracellular DNA repair proteins can enhance the sensitivity of some tumor cells to chemotherapy (see Dolan et al. ""Cancer Research" 51 pp. 3367-3372 (1991) (Dolan et al., Cancer Res.,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/352A61K31/585A61K31/505A61K31/17A61P35/00
Inventor 孔庆忠
Owner 山东同科供应链股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com